Business Wire

CA-ANDERSEN-GLOBAL

20.9.2019 11:50:05 CEST | Business Wire | Pressemeddelelse

Del
Andersen Global udvider rækkevidde i London

Andersen Global fortsætter sin udvidelse i Storbritannien, idet Miles Dean, Zoe Wyatt og deres team slutter sig til Andersen Tax LLP-teamet i Storbritannien. Denne tilføjelse giver yderligere dybde til koncernen i London og forbedrer teamets evne til at arbejde sammen med kunder på en helhedsorienteret måde og yde uovertruffen og effektiv service. Andersen Global er repræsenteret fem steder i Storbritannien igennem sine medlems- og samarbejdsfirmaer.

Miles og Zoe har tidligere arbejdet for Milestone, som blev grundlagt af Miles Dean i 2008, og Zoe Wyatt blev partner i 2015. Som en del af Andersen Tax LLP vil disse partnere fortsat levere en bred vifte af internationale skattetjenester til virksomheder og private kunder, investeringsfonde og ejendomsinvestorer og -udviklere. Milestone underskrev en samarbejdsaftale med Andersen Global i 2018, og den positive indvirkning af dette forhold har ført til, at Miles, Zoe og deres team nu slutter sig til Andersen Global-medlemsfirmaet i Storbritannien.

“Det var enormt vigtigt for os at sikre, at vi er i stand til at yde det bedste for vores kunder. Vi ser virkelig frem til at fortsætte med at levere effektiv service og fordelen ved ekspertise fra de bedste rundt omkring i verden som en del af Andersen Global-familien,” sagde Miles Dean, grundlæggende partner hos Milestone og nu partner hos Andersen Tax LLP. “Jeg sætter pris på ​​at samarbejde med ligesindede partnere over hele kloden, og vores tid med Andersen Global, både som et samarbejdsfirma og nu som en del af det britiske medlemsfirma, har vist en fælles forpligtelse til at levere service af høj kvalitet.”

“At have Miles og Zoe som partnere i vores team er en naturlig udvikling, da vi har arbejdet tæt sammen med dem i mere end to år. Som en del af Andersen Tax LLP vil teamets komplementære ekspertise og erfaring give vores bredere koncern et markant løft på det dynamiske britiske marked, idet vi udvider vores rækkevidde i hele landet og globalt,” sagde George McCracken, administrerende direktør for Andersen Tax LLP.

“Miles, Zoe og deres team giver den slags unikke ekspertise og dedikation, der uden tvivl skiller sig ud fra resten. Teamet er indbegrebet af de egenskaber, som vi værdsætter hos Andersen, såsom gennemsigtighed, uovertruffen service og ledelse,” sagde Mark Vorsatz, bestyrelsesformand for Andersen Global og administrerende direktør for Andersen. “Idet vi fortsætter med at tilføje og udvide vores evner for kunder i Storbritannien, bygger vi videre på det eksisterende fundament i regionen og viser vores ildhu for at tilbyde effektive services over hele kloden.”

Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, der består af skatte- og juraeksperter fra hele verden. Andersen Global blev etableret af det amerikanske medlemsfirma Andersen Tax LLC i 2013 og har nu over 4.500 eksperter verden over og er repræsenteret mere end 149 steder igennem medlems- og samarbejdsfirmaer.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye